4.7 Review

Therapeutic potential of bicyclol in liver diseases: Lessons from a synthetic drug based on herbal derivative in traditional Chinese medicine

Journal

INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 91, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.intimp.2020.107308

Keywords

Traditional Chinese medicine; Bicyclol; Liver disease; Pharmacological activity; Pharmacokinetic; Ferroptosis

Funding

  1. Science and Technology Program of Tianjin [19PTZWHZ00090]
  2. Natural Science Foundation of Tianjin City [18JCZDJC45200]

Ask authors/readers for more resources

Bicyclol, a novel chemical drug derived from Schisandra chinensis, shows therapeutic potential in various liver conditions with a wide range of pharmacological properties. Pharmacokinetic studies indicate its safety and lack of drug interactions, making it a potential candidate for liver diseases worldwide. Further research is needed to understand its molecular mechanisms for increased potency in clinical use.
Bicyclol, an innovative chemical drug with proprietary intellectual property rights in China, is based on derivative of traditional Chinese medicine (TCM) Schisandra chinensis (Wuweizi) of North. Mounting data has proved that bicyclol has therapeutic potential in various pathological conditions in liver. In this narrative review, we provide the first summary of pharmacological activities, pharmacokinetic characteristics and toxicity of bicyclol, and discuss future research perspectives. Our results imply that bicyclol has a wide spectrum of pharmacological properties, including anti-viral, anti-inflammatory, immuno-regulatory, anti-oxidative, antisteatotic, antifibrotic, antitumor, cell death regulatory effects and modulation of heat shock proteins. Pharmacokinetic studies have indicated that bicyclol is the main substrate of CYP3A/2E1. Additionally, no obvious drug interactions have been found when bicyclol is administered simultaneously with other prescriptions. Furthermore, the results of chronic toxicity have strongly addressed that bicyclol has no noticeable toxic effects on all biochemical indices and pathological examinations of the main organs. In view of good pharmacological actions and safety, bicyclol is anticipated to be a potential candidate for various liver diseases, including acute liver injury, fulminant hepatitis, non-alcoholic fatty liver disease, fibrosis and hepatocellular carcinoma. Further studies are therefore required to delineate its molecular mechanisms and targets to confer this well-designed drug a far greater potency. We hope that bicyclol-based therapeutics for liver diseases might be broadly used in clinical practice worldwide.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available